文献速递心律失常

中国非瓣膜性心房颤动患者华法林治疗现状:单中心分析

[Current status of warfarin therapy in Chinese patients with nonvalvular atrial fibrillation: a single center analysis].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2016-01-01

该单中心研究分析2014年1月至6月住院的600例非瓣膜性心房颤动患者,发现162例(28.9%)接受华法林治疗,428例(71.3%)存在未治疗、过度治疗或治疗不当,结论认为需要加强努力以改善中国NVAF人群的抗栓治疗现状。

要点

  • 600例NVAF患者中162例(28.9%)接受华法林治疗,244例(43.6%)用阿司匹林,137例(24.5%)未接受抗栓治疗。
  • 与抗栓治疗相关的因素包括持续性房颤、射频消融、他汀使用、抗心律失常治疗及阿司匹林使用。
  • 428例(71.3%)患者存在未治疗、过度治疗或治疗不当,作者认为需加强努力改善抗栓治疗现状。

核心结论

  • 本研究中428例(71.3%)NVAF患者存在未治疗、过度治疗或治疗不当,作者认为需要加强努力以改善中国NVAF人群的抗栓治疗现状。

研究设计与样本

  • 单中心分析,纳入2014年1月至6月于该院住院的NVAF患者600例,分析基线临床特征、并发症、合并用药及抗栓治疗等临床数据。
  • 采用t检验、卡方检验、Fisher精确检验及二元logistic回归分析上述指标与华法林使用的关系。

主要发现

  • 600例患者中560例(93.3%)CHA2DS2-VASc评分≥1,162例(28.9%)接受华法林(单用或联合抗血小板药),244例(43.6%)接受阿司匹林,137例(24.5%)未接受抗栓治疗。
  • 600例中172例(28.7%)治疗符合现行指南推荐,266例(44.3%)治疗不当,23例(3.8%)过度治疗,139例(23.2%)未接受抗栓治疗。
  • 与抗栓治疗相关的因素包括持续性房颤(OR=3.92,95%CI 1.43-10.78,P=0.008)、射频消融(OR=26.82,95%CI 7.03-102.38,P<0.001)、他汀使用(OR=3.35,95%CI 1.30-8.63,P=0.012)、抗心律失常治疗(OR=3.42,95%CI 1.29-9.07,P=0.014)及阿司匹林(OR=0.02,95%CI 0-0.07,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the current status of warfarin therapy and the related factors in patients with nonvalvular atrial fibrillation(NVAF) based on data from a single center. Methods: We analyzed clinical data including baseline clinical characteristics, complications, concomitant medications and anti-thrombotic treatment in patients who were admitted to our hospital with NVAF from January 2014 to June 2014. The data were analyzed by t test, Chi-square test, fisher exact test and binary logistic regression analysis for the above indexes with warfarin utilization. Results: A total of 600 patients enrolled in this study, 560(93.3%) patients had a CHA2DS2-VASc score≥1, 162(28.9%) patients received warfarin (alone or in combination with antiplatelet agents), 244(43.6%) patients were treated with aspirin, 137(24.5%) patients did not receive anti-thrombotic treatment. Of the 600 patients, 172(28.7%) patients were treated in line with the current guideline recommendation, 266(44.3%) patients were treated improperly, 23(3.8%) patients were over-treated, 139(23.2%) patients received no anti-thrombotic treatment. Factors associated with anti-thrombotic treatment were persistent atrial fibrillation (OR=3.92, 95%CI 1.43-10.78, P=0.008), radiofrequency ablation (OR=26.82, 95%CI 7.03-102.38, P<0.001), the use of statins (OR=3.35, 95%CI 1.30-8.63, P=0.012), anti-arrhythmic therapy (OR=3.42, 95%CI 1.29-9.07, P=0.014), and aspirin (OR=0.02, 95%CI 0-0.07, P<0.001). Conclusions: In this study, 428 (71.3%) NVAF patients were either un-treated, over-treated or inadequately treated. Intensive efforts are necessary to improve anti-thrombotic therapy status in NVAF population in China.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao SJ, Zhao HW, Wang XP, et al. [Current status of warfarin therapy in Chinese patients with nonvalvular atrial fibrillation: a single center analysis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016. PMID: 27903391. doi:10.3760/cma.j.issn.0253-3758.2016.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。